A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder Function

Relapsing-Remitting Multiple Sclerosis Clinical Trial

— TRUST  

Official title:

Phase IV, Proof of Concept Study to Evaluate Tysabri Effectiveness in RRMS Patient Bladder Function

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00818038
• Other study ID #: US 006-08-NAT
• Status: Completed
• Phase: N/A
• First received: January 5, 2009
• Last updated: June 25, 2014
• Start date: March 2009
• Est. completion date: March 2011

Study information

• Verified date: June 2014
• Source: Biogen
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

The primary objective of the study was to measure the change in bladder function as measured by Urogenital Distress Inventory (UDI)-6 compared to baseline over 6 months of Tysabri treatment. Secondary objectives were to (i) measure change from baseline over 6 months of Tysabri treatment in the number of urinary incontinence episodes per participant per week, (ii) measure change from baseline over 6 months of Tysabri treatment in the number of micturitions per participant per day, (iii) measure change in The North American Research Committee on Multiple Sclerosis (NARCOMS) bladder/bowel subscale (PSB) scores from baseline over 6 months of Tysabri treatment and (iv) measure change in Incontinence Impact Questionnaire (IIQ)-7 scores from baseline over 6 months of Tysabri treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: March 2011
• Est. primary completion date: March 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 85 Years

Eligibility

Key Inclusion Criteria:

Participants are eligible to be screened for this study if all of the following criteria are met:

• Patient must meet all prescribing criteria for TYSABRI® and eligible for the TOUCH™ program.

• If utilizing medications for symptoms of bladder dysfunction (such as incontinence, urgency etc), subjects will need to remain on a stable dose of medication(s) for at least one month prior to and for duration of study.

• If utilizing medications that affect urinary output (e.g. anticholinergics, diuretics, etc.), subjects will need to remain on a stable dose of medication(s) for at least one month prior to study entry and for the duration of the study.

• Able to provide written informed consent.

• Patient must be willing to maintain current hydration habits and caffeine intake for the duration of the study.

Participants will be selected for enrollment if all of the following criteria are met:

• Screening Visit urinary incontinence defined as:

• Greater than or equal to 3 incontinence episodes per week or greater than or equal to 8 micturitions per day (both mean numbers).

• Screening Visit score on the UDI-6 of more than or equal to 6.

• Screening Visit EDSS 0 - 6.5

Key Exclusion Criteria:

Candidates will be excluded from study screening if any of the following exclusion criteria exist:

• Primary progressive, secondary progressive, or progressive relapsing MS. Primary progressive, secondary progressive or progressive relapsing multiple sclerosis are defined by Lublin and Reingold (Lublin and Reingold, 1996) or EDSS >6.5.

• Current or previous history of Progressive Multifocal Leukencephalopathy (PML).

• A clinically significant infectious illness (e.g., cellulitis, abscess, pneumonia, septicemia) within 30 days.

• History of recurrent or chronic urinary tract infection or a urinary tract infection within the preceding 30 days prior to Week 0 (diagnosis based on clinical history and Screening Visit urinalysis and urine culture).

• Patients who have in-dwelling foley catheter or a suprapubic catheter.

• Patients with a history of symptomatic benign prostatic hyperplasia (BPH) or a history of prostate cancer.

• History of, or abnormal laboratory results indicative of, any significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, gastrointestinal, dermatologic, psychiatric, renal, and/or other major disease, that, in the opinion of the investigator, would preclude the administration of natalizumab for the duration of the study.

• Subject with history of malignancy within the past 2 years, with the exception of basal cell carcinoma that has been treated.

• History of severe allergic or anaphylactic reactions or known drug hypersensitivity.

• Any prior treatment with the following medications: Natalizumab (TYSABRI®)

• Nursing mothers, pregnant women, and women planning to become pregnant while in study.

• Any other reasons that, in the opinion of the Investigator and/or Sponsor, the subject is determined to be unsuitable for enrollment into this study.

• Unwillingness or inability to comply with the requirements of this protocol including the presence of any condition (physical, mental, or social) that is likely to affect the subject's ability to comply with the study protocol.

• History of alcohol or drug abuse within 2 years prior to randomization.

• Female subjects who are not postmenopausal for at least 1 year, surgically sterile, or willing to use a medically acceptable method of birth control during the study. The rhythm method is not to be used as the sole method of contraception.

Participants will be determined as screen failures if any of the following criteria apply:

• Abnormal blood tests, performed at the screening visit, which exceed any of the limits defined below:

1. ALT/ SGPT, or AST/ SGOT more than three times the upper limit of normal (i.e., 3xULN).

2. Total white blood cell (WBC) count less than 2,300/mm3.

3. Platelet count less than 100,000/mm3.

4. Creatinine more than 2xULN.

• Screening Visit urinary incontinence defined as less than 3 incontinence episodes per week or less than 8 micturitions per day (both mean numbers).

• Screening Visit score on the UDI-6 of less than 6.

• Screening Visit EDSS more than 6.5.

NOTE: Other protocol defined inclusion/exclusion criteria may apply.

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Multiple Sclerosis
• Multiple Sclerosis, Relapsing-Remitting
• Relapsing-Remitting Multiple Sclerosis
• Sclerosis

Intervention

Drug:
• BG0002 (natalizumab)
Participants who are newly prescribed TYSABRI, but have not received their first infusion, will be invited to participate.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Biogen

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in bladder function as measured by UDI-6 compared to baseline over 6 months of TYSABRI treatment.		Baseline and 6 months	No
Secondary	Change from baseline over 6 months of TYSABRI treatment in the number of urinary incontinence episodes per participant per week.		Baseline and 6 months	No
Secondary	Change from baseline over 6 months of TYSABRI treatment in the number of micturitions per participant per day.		Baseline and 6 months	No
Secondary	Change in NARCOMS PSB scores from baseline over 6 months of TYSABRI treatment.		Baseline and 6 months	No
Secondary	Change in IIQ-7 scores from baseline over 6 months of TYSABRI treatment.		Baseline and 6 months	No